- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00127387
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
June 22, 2012 updated by: The University of Texas Health Science Center at San Antonio
A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia
Patients who receive radiation therapy often have fatigue or a decrease in feeling well causing a "wasting" away.
For patients with advanced disease of lung cancer, prostate cancer, or cancer that has spread to the bone, it is hoped that this drug may decrease this.
If patients feel better during treatments they can complete the therapy without any breaks in treatment.
For treatment to be most effective, it should be given in the amount needed, on a particular schedule.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Subjects will be placed in a group to receive either the drug enbrel, or a placebo.
The radiation therapy treatments are as they would be given if the person was not on a research study.
The selection of the group a patient is in is done by random, like flipping a coin.
The doctor is not able to influence which group anyone is selected for.
As is done routinely, radiation therapy is given Monday through Friday for about 4 to 6 weeks.The injections of enbrel or placebo are given two times a week.
The enbrel or placebo is given as an injection directly under the skin with a small needle.
Study Type
Interventional
Enrollment (Anticipated)
54
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced lung, prostate, or bony metastasis for cancer
- Performance status (PS) of 3 or less
- Good lab test results with albumin of at least 2.5
- Radiation therapy of at least 4000Gy in 4 weeks
Exclusion Criteria:
- Poor PS
- Planned radiation therapy for less than 4 weeks or 4000Gy
- Limited disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Determine if the subjects who received the enbrel study drug had a better quality of life than the subjects who received placebo
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety profile for enbrel taken by this group of individuals
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Charles R Thomas, Jr, MD, U Texas Health Science Center San Antonio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2001
Primary Completion (Actual)
September 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
August 3, 2005
First Submitted That Met QC Criteria
August 4, 2005
First Posted (Estimate)
August 5, 2005
Study Record Updates
Last Update Posted (Estimate)
June 26, 2012
Last Update Submitted That Met QC Criteria
June 22, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Body Weight
- Prostatic Diseases
- Musculoskeletal Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Bone Diseases
- Body Weight Changes
- Emaciation
- Weight Loss
- Prostatic Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Bone Neoplasms
- Cachexia
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Etanercept
Other Study ID Numbers
- 001-0015-211
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Metastasis
-
Betta Pharmaceuticals Co., Ltd.Recruiting
-
BayerCompleted
-
BayerCompletedNeoplasm Metastasis / Bone and BonesBelgium, Spain, Taiwan, United States, Japan, Russian Federation, Canada, Finland, Korea, Republic of, Singapore, Australia, Germany, Israel, United Kingdom, Italy, France, Poland, Brazil, Czechia, Norway, Sweden, Hong Kong
-
National Cancer Institute (NCI)TerminatedCancer | Neoplasm Metastasis | Metastasis | Neoplasm | Radiation OncologyUnited States
-
MedtronicNeuroCompletedMetastasis Spine | Metastasis to BoneUnited States, Luxembourg, Germany, France, Canada
-
Cho Ray HospitalUniversity of Medicine and Pharmacy at Ho Chi Minh CityRecruitingSynchronous Neoplasm | Liver Metastasis Colon CancerVietnam
-
Assiut UniversityNot yet recruiting
-
Amsterdam UMC, location VUmcRecruiting
-
Synthorx, Inc, a Sanofi companyRecruitingMetastasisUnited States, Australia, Singapore, Spain, Argentina, Chile
Clinical Trials on Enbrel
-
ASIS CorporationUnknown
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAnkylosing SpondylitisDenmark, Sweden, Finland, United Kingdom
-
Samsung Bioepis Co., Ltd.Completed
-
Coherus Biosciences, Inc.ShireCompletedPlaque PsoriasisUnited States, Israel, Australia, Germany, South Africa, Poland, Canada
-
PfizerCompletedRheumatoid ArthritisFrance, Germany, Italy, Sweden, United Kingdom, Netherlands, Denmark, Finland, Norway
-
mAbxience Research S.L.Recruiting
-
GlaxoSmithKlineCompleted
-
AmgenCompleted
-
Coherus Biosciences, Inc.Daiichi Sankyo Co., Ltd.CompletedRheumatoid ArthritisUnited States, Spain, Israel, Belarus, Japan, Poland, Hungary, South Africa, Germany, Russian Federation, France, United Kingdom